Study of Tirzepatide Added to Automated Insulin Delivery in Adults Aged 18-65 With Type 1 Diabetes to Improve Blood Sugar Control

What this Trial Is About

Researchers are investigating whether adding a new medicine called tirzepatide, a glucose-dependent insulinotropic polypeptide GIPglucagon-like peptide-1 receptor agonist GLP-1RA, to usual insulin therapy can improve blood sugar control in adults with type 1 diabetes T1D. The study is designed as a prospective, randomized clinical trial to evaluate this combinations effect on glucose management, aiming to provide new options beyond standard insulin treatment. About 30% of adults with T1D currently meet recommended blood sugar targets, highlighting the need for improved therapies. The study will enroll adults aged 18 to 65 years with T1D diagnosed for at least 12 months who are already using automated insulin delivery AID systems. Participants will be randomly assigned to either continue their standard care or to add once-weekly injections of tirzepatide, starting at a low dose of 2.5 mg and increasing to 5 mg weekly for 12 weeks. The trial includes a 4-week dose titration phase followed by 12 weeks of treatment, comparing glucose control outcomes between groups. Participants will wear a continuous glucose monitor CGM and share their glucose and insulin data throughout the 16-week study. Researchers will assess time spent within target glucose ranges, changes in blood sugar levels, insulin doses, and body weight. Safety and adherence will be monitored during the trial. The study aims to gather important data on whether tirzepatide can help improve glucose control and quality of life for adults living with T1D.

GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes